首頁/股票/TNGX

TNGX

USD

Tango Therapeutics Inc.

$8.010+0.120 (1.521%)

即時價格

Healthcare

生物科技

美國

價格圖表

Loading Chart...

關鍵指標

市場指標

公司基本面

交易統計

市場指標

開盤

$7.890

最高

$8.170

最低

$7.470

交易量

2.98M

公司基本面

市值

1.1B

行業

生物科技

國家

United States

交易統計

平均交易量

2.68M

交易所

NGM

貨幣

USD

52週範圍

最低 $1.03當前 $8.010最高 $9.7

相關新聞

2025年10月29日 · 上午11:00

GlobeNewswire

Tango Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that it will report third quarter 2025 financial results on November 4, 2025 at 9:00am ET, before the open of the U.S.

Tango Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

2025年10月24日 · 下午12:01

Analyst Upgrades

Guggenheim Maintains Buy on Tango Therapeutics, Raises Price Target to $12

Guggenheim analyst Charles Zhu maintains Tango Therapeutics with a Buy and raises the price target from $10 to $12.

Guggenheim Maintains Buy on Tango Therapeutics, Raises Price Target to $12

2025年10月23日 · 上午11:20

GlobeNewswire

Tango Therapeutics Announces $225 Million Financing

BOSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines,

Tango Therapeutics Announces $225 Million Financing

2025年10月23日 · 上午11:00

GlobeNewswire

Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers

– 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months with an objective response rate (ORR) of 25% – – Combination studies with RAS(ON) inhibitors ongoing, data anticipated 2026 – – 49%